Seres Therapeutics, a leading microbiome therapeutics company, will be hosting a conference call and live webcast on May 8, 2024, at 8:30 a.m. ET to discuss its financial results for the first quarter of 2024, as well as provide updates on its business endeavors.
Interested participants can access the conference call by dialing 800-715-9871 (domestic) or 646-307-1963 (international), using the conference ID number 5686561. Alternatively, the live webcast can be joined by visiting the “Investors and News” section of the Seres website at www.serestherapeutics.com.
Those unable to attend the live event can access a webcast replay on the Seres website approximately two hours after the call. The replay will be available for approximately 21 days and can provide valuable insights into the discussions held during the conference.
Seres Therapeutics is a commercial-stage company that focuses on developing innovative microbiome therapeutics for treating serious diseases. In April 2023, its lead program VOWST™ received approval from the U.S. FDA as the first orally administered microbiome therapeutic for preventing the recurrence of C. difficile infection (CDI) in adults who have undergone antibacterial treatment for recurrent CDI. Seres is working in collaboration with Nestlé Health Science to commercialize this groundbreaking treatment.
Additionally, Seres is currently evaluating SER-155 in a Phase 1b study involving patients who have undergone allogeneic hematopoietic stem cell transplantation. This research has the potential to unlock new possibilities in the field of microbiome therapeutics.
For more information about Seres Therapeutics and its innovative treatments, please visit their official website at www.serestherapeutics.com.
Contact: [email protected]
Seres Therapeutics, a leading microbiome therapeutics company, is set to discuss its financial results for the first quarter of 2024, as well as provide updates on its business endeavors in a conference call and live webcast on May 8, 2024, at 8:30 a.m. ET. The company’s primary focus is on developing innovative microbiome therapeutics for treating serious diseases.
One of Seres Therapeutics’ notable achievements is the approval of its lead program, VOWST™, by the U.S. FDA in April 2023. VOWST™ is the first orally administered microbiome therapeutic approved for preventing the recurrence of C. difficile infection (CDI) in adults who have undergone antibacterial treatment for recurrent CDI. This groundbreaking treatment has the potential to make a significant impact on patient care.
Seres Therapeutics has also formed a collaboration with Nestlé Health Science to commercialize VOWST™. This partnership aims to leverage both companies’ expertise to bring this innovative treatment to the market efficiently.
In addition to VOWST™, Seres Therapeutics is currently evaluating SER-155 in a Phase 1b study. This study involves patients who have undergone allogeneic hematopoietic stem cell transplantation. The research on SER-155 has the potential to unlock new possibilities in the field of microbiome therapeutics, further expanding the company’s portfolio of innovative treatments.
It is important to note that while Seres Therapeutics has achieved significant milestones, there are challenges and controversies associated with the field of microbiome therapeutics. The effectiveness of microbiome-based therapies and their long-term impacts are still being explored. Regulatory hurdles and concerns about commercial viability also exist in this emerging field.
To participate in the conference call, interested individuals can dial 800-715-9871 (domestic) or 646-307-1963 (international), using the conference ID number 5686561. Alternatively, the live webcast can be accessed on the “Investors and News” section of the Seres website at www.serestherapeutics.com. Those unable to attend the live event can access the webcast replay on the Seres website approximately two hours after the call, which will be available for approximately 21 days.
For more information about Seres Therapeutics and its innovative treatments, please visit their official website at www.serestherapeutics.com.
Contact: [email protected]